DLBCL - Diffuse Large B Cell Lymphoma: Clinical Trials

3 trials for DLBCL - Diffuse Large B Cell Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting, 1 not yet recruiting. 3 Not applicable.

By phase and status

PhaseTrialsStatus
Not applicable3Recruiting 2, Not yet recruiting 1

Follow DLBCL - Diffuse Large B Cell Lymphoma: new trials by email Literature Review of DLBCL - Diffuse Large B Cell Lymphoma trials Research Report on DLBCL - Diffuse Large B Cell Lymphoma

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL
Orelabrutinib Combined with Pola-R-CHP Regimen - DLBCL - Diffuse Large B Cell Lymphoma, Intermediate-High Risk
Not applicableRecruitingThe First Affiliated Hospital of Xiamen University302026-08-302026-08-21
Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL
Rituximab+Ifosfamide+Mesna+Mitoxantrone hydrochloride liposome+Etoposide, Rituximab+Gemcitabine+Oxaliplatin - DLBCL - Diffuse Large B Cell Lymphoma
Not applicableNot yet recruitingThe First Affiliated Hospital with Nanjing Medical University702026-02-252026-02-05
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
Hematolo-GIST Training, Participants Appointment - Lymphoma, B-Cell, Lymphoma
Not applicableRecruitingMemorial Sloan Kettering Cancer Center482023-07-032026-10-13

Narrower conditions

Dendritic Cell Sarcoma, Interdigitating (3)  ·  Lymphoma (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)

Broader conditions

Hemic and Lymphatic Diseases (3)  ·  Histiocytic Disorders, Malignant (3)  ·  Histiocytosis (3)  ·  Lymphatic Diseases (3)  ·  Neoplasms (3)  ·  Neoplasms by Histologic Type (3)  ·  Immune System Diseases (1)  ·  Immunoproliferative Disorders (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Lymphoproliferative Disorders (1)

Interventions

Cyclophosphamide (1)  ·  Doxorubicin (1)  ·  Prednisone (1)  ·  Rituximab (1)  ·  orelabrutinib (1)  ·  polatuzumab vedotin (1)

Sponsors

Memorial Sloan Kettering Cancer Center (1)  ·  The First Affiliated Hospital of Xiamen University (1)  ·  The First Affiliated Hospital with Nanjing Medical University (1)

Countries

China (1)  ·  United States (1)

Top investigators

Bing Xu, PhD,MD (1)  ·  Jinhua Liang (1)  ·  Kelly McConnell, PhD (1)  ·  Wei Xu (1)